Application progress of nucleic acid aptamers in targeted drug delivery system

XIONG Ye; TAI ZongGuang; Li Qiang

doi:10.3969/j.issn.1006-0111.2015.06.003

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 33 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2015 > 33(6): 490-493,532

XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003

Citation:

XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003

Application progress of nucleic acid aptamers in targeted drug delivery system

doi: 10.3969/j.issn.1006-0111.2015.06.003

1.
Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
2.
Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China

Received Date: 2013-11-04
Rev Recd Date: 2014-12-24

Abstract

Aptamers are single stranded oligonucleotides that have high affinity and specificity towards a wide range of target molecules. Owing to the indispensable advantages, aptamers have wildly prospects and have become a research hotspot in targeted drug delivery system (TDDS). In this article, application advantage and progress of aptamers in TDDS were briefly reviewed, the problems and prospects were also discussed.
- nucleic acid aptamers,
- targeted drug delivery,
- application progress

References

[1]	Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Biotechnol, 2011, 29(12): 634-640.
[2]	Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery[J]. Pharmaceuticals, 2011, 4(8): 1137-1157.
[3]	Taouji S, Dausse E, Evadé L, et al. Advances in binder identification and characterisation: the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554.
[4]	Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy[J]. Chem Rev, 2007, 107(9): 3715-3743.
[5]	Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen[J]. Cancer Res, 2002, 62(14): 4029-4033.
[6]	Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells[J]. Cancer Res, 2004, 64(21): 7668-7672.
[7]	Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed, 2006, 45(48): 8149-8152.
[8]	Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function[J]. J Immunol, 1998, 160(11): 5209-5212.
[9]	Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110.
[10]	Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797-1808.
[11]	Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands[J]. Cell Signal, 2005, 17(10): 1183-1193.
[12]	Li N, Larson T, Nguyen HH, et al. Directed evolution of gold nanoparticle delivery to cells[J]. Chem Commun, 2010, 46(3): 392-394.
[13]	Prebet T, Lhoumeau A-C, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome[J]. Blood, 2010, 116(13): 2315-2323.
[14]	Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study[J]. P Natl Acad Sci USA, 2006, 103(32): 11838-11843.
[15]	Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection[J]. Chem Eur J, 2008, 14(6): 1769-1775.
[16]	Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chem Bio Chem, 2009, 10(5): 862-868.
[17]	o'donoghue MB. A liposome-based nanostructure for aptamer directed delivery[J]. Chem Commun, 2010, 46(2): 249-251.
[18]	胡萍. 肿瘤发生和 MUC1 及 Survivin 研究进展[J]. 中国医药指南, 2013, 11(1): 69-70.
[19]	Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831.
[20]	Gendler SJ. MUC1, the renaissance molecule[J]. J Mammary Gland Biol Neoplasia, 2001, 6(3): 339-353.
[21]	Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells[J]. Nucleic Acids Res, 2009, 37(3): 866-876.
[22]	Do Kwon Y, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops[J]. P Natl Acad Sci USA, 2012, 109(15): 5663-5668.
[23]	Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy[J]. Mol Ther, 2008, 16(8): 1481-1489.
[24]	Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism[J]. Cancer Res, 2010, 70(21): 8617-8629.
[25]	Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes[J]. Angew Chem Int Ed, 2009, 48(35): 6494-6498.
[26]	胡艳玲, 史爱欣, 傅得兴, 等. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576.
[27]	Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graef Arch Clin Exp, 2010, 248(7): 915-930.
[28]	Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation[J]. Chem Bio Chem, 2002, 3(8): 717-725.
[29]	Jeon SH, Kayhan B, Ben-Yedidia T, et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin[J]. J Biol Chem, 2004, 279(46): 48410-48419.
[30]	Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor Ⅸa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis[J]. Curr Opin Mol Ther, 2009, 11(6): 707-715.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3513) PDF downloads(291) Cited by()

Proportional views

Application progress of nucleic acid aptamers in targeted drug delivery system

1. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

2. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China

Received Date: 2013-11-04

Rev Recd Date: 2014-12-24

Key words:

Abstract: Aptamers are single stranded oligonucleotides that have high affinity and specificity towards a wide range of target molecules. Owing to the indispensable advantages, aptamers have wildly prospects and have become a research hotspot in targeted drug delivery system (TDDS). In this article, application advantage and progress of aptamers in TDDS were briefly reviewed, the problems and prospects were also discussed.

HTML

Reference (30)

[1]	Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Biotechnol, 2011, 29(12): 634-640.
[2]	Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery[J]. Pharmaceuticals, 2011, 4(8): 1137-1157.
[3]	Taouji S, Dausse E, Evadé L, et al. Advances in binder identification and characterisation: the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554.
[4]	Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy[J]. Chem Rev, 2007, 107(9): 3715-3743.
[5]	Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen[J]. Cancer Res, 2002, 62(14): 4029-4033.
[6]	Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells[J]. Cancer Res, 2004, 64(21): 7668-7672.
[7]	Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed, 2006, 45(48): 8149-8152.
[8]	Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function[J]. J Immunol, 1998, 160(11): 5209-5212.
[9]	Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110.
[10]	Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797-1808.
[11]	Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands[J]. Cell Signal, 2005, 17(10): 1183-1193.
[12]	Li N, Larson T, Nguyen HH, et al. Directed evolution of gold nanoparticle delivery to cells[J]. Chem Commun, 2010, 46(3): 392-394.
[13]	Prebet T, Lhoumeau A-C, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome[J]. Blood, 2010, 116(13): 2315-2323.
[14]	Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study[J]. P Natl Acad Sci USA, 2006, 103(32): 11838-11843.
[15]	Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection[J]. Chem Eur J, 2008, 14(6): 1769-1775.
[16]	Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chem Bio Chem, 2009, 10(5): 862-868.
[17]	o'donoghue MB. A liposome-based nanostructure for aptamer directed delivery[J]. Chem Commun, 2010, 46(2): 249-251.
[18]	胡萍. 肿瘤发生和 MUC1 及 Survivin 研究进展[J]. 中国医药指南, 2013, 11(1): 69-70.
[19]	Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831.
[20]	Gendler SJ. MUC1, the renaissance molecule[J]. J Mammary Gland Biol Neoplasia, 2001, 6(3): 339-353.
[21]	Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells[J]. Nucleic Acids Res, 2009, 37(3): 866-876.
[22]	Do Kwon Y, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops[J]. P Natl Acad Sci USA, 2012, 109(15): 5663-5668.
[23]	Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy[J]. Mol Ther, 2008, 16(8): 1481-1489.
[24]	Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism[J]. Cancer Res, 2010, 70(21): 8617-8629.
[25]	Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes[J]. Angew Chem Int Ed, 2009, 48(35): 6494-6498.
[26]	胡艳玲, 史爱欣, 傅得兴, 等. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576.
[27]	Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graef Arch Clin Exp, 2010, 248(7): 915-930.
[28]	Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation[J]. Chem Bio Chem, 2002, 3(8): 717-725.
[29]	Jeon SH, Kayhan B, Ben-Yedidia T, et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin[J]. J Biol Chem, 2004, 279(46): 48410-48419.
[30]	Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor Ⅸa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis[J]. Curr Opin Mol Ther, 2009, 11(6): 707-715.

Message Board

Application progress of nucleic acid aptamers in targeted drug delivery system

doi: 10.3969/j.issn.1006-0111.2015.06.003

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views